Non-celiac gluten sensitivity: a work-in-progress entity in the spectrum of wheat-related disorders.
Study Goal
The researchers aimed to understand the effects of a gluten-free diet on non-celiac gluten sensitivity, including symptom resolution and potential biomarkers.
Results Summary
The study found that symptoms of non-celiac gluten sensitivity resolved within hours or days after gluten withdrawal and recurred upon reintroduction. IgG anti-gliadin antibodies disappeared quickly after starting a gluten-free diet.
Population
Primarily young women, rarely children.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten withdrawal | decrease | symptoms | patients without celiac disease and wheat allergy | in a few hours or days | disappear | #1 |
gluten ingestion | increase | symptoms | patients without celiac disease and wheat allergy | rapidly | recur rapidly | #2 |
gluten-free diet | decrease | IgG anti-gliadin antibodies | half of patients | quickly | disappear quickly | #3 |
gluten-free diet | decrease | symptoms | half of patients | - | disappear | #4 |
Non-celiac gluten sensitivity is an undefined syndrome with gastrointestinal and extra-intestinal manifestations triggered by gluten in patients without celiac disease and wheat allergy. The pathogenesis involves immune-mediated mechanisms requiring further research. Symptoms disappear in a few hours or days after gluten withdrawal and recur rapidly after gluten ingestion. Besides gluten, other wheat proteins as well as fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs) may contribute to this syndrome. This syndrome occurs mainly in young women, being rare in children. Its prevalence ranges from 0.6% to 6%, based on primary or tertiary care center estimates. No biomarker is available, but half of patients tests positive for IgG anti-gliadin antibodies, which disappear quickly after gluten-free diet together with symptoms. Also, genetic markers are still undefined. Although currently limited to a research setting, double-blind, placebo-controlled, cross-over trial strategy is recommended to confirm the diagnosis. Treatment is based on dietary restriction with special care to nutrient intake.